Medtronic, Inc.

Vitatron Medical B. V.

Vitafin N.v.

Willem Boute

Mattias Rouw

Jos W Van Hove

Frederik H Wittkampf

Peter M Van Dam

David R Hampton

Malcolm J Begemann

Giorgio Corbucci

Kornelis A Mensink

Wilbert Wesselink

Gustaaf A P Stoop

Gerrit W Van Arragon

Geeske Van Oort

Patrick Scholten

Josephus P A Smit

Harm H Van Bolhuis

Marijn Van Gemert

Anna Pietersma

Guus Stoop

Bert A Albers

Josephus Smit

Gustaaf AP Stoop

A system and method are provided for the detection of a heart-related condition by obtaining information in real-time when a condition is initially identified as potentially occurring. A physical exercise and recovery episode is initially detected from physiological signals sensed in a patient. Once detected, a HR-ST segment deviation hysteresis analysis is performed in an implantable medical device (IMD) from certain physiological signals over portions of the exercise and recovery episode to identify the probability that a certain condition is occurring. Once a desired level of probability that the heart-related condition has been detected exists, data utilized in the analysis can be transmitted remotely for clinical review and confirmation of the device's detection of the condition. The patient may be prompted to answer questions related to symptoms that patient is experiencing through an input device in order further confirm the probability that the condition is occurring in the patient.

System and method for improved ischemia and acute myocardial infarction detection

An implantable medical device operates to promote intrinsic ventricular depolarization according to a pacing protocol. When a cardiac rate exceeds a predetermined threshold, the implantable medical device modifies the pacing protocol parameters to promote AV synchrony.

Implantable medical device with ventricular pacing management of elevated heart rates

An implantable medical device and associated method predict syncope based on detecting a change in ejection time. A physiological signal is sensed that is responsive to mechanical changes associated with the cardiac ejection phase. A time interval corresponding to cardiac ejection time is detected from the physiological signal. A sudden change in the time interval is used as a predictor of syncope and causes a patient alert to be generated in response to the detected change.

System and method to monitor ejection time and QT interval to alert patients before syncopal events

An implantable medical device uses a method for dynamically managing physiological signal monitoring. A physiological signal is sensed for detecting physiological events in response a first threshold. A determination is made whether a second threshold has been met in response to detecting physiological events. If the second threshold has been met, detailed monitoring of the physiological events is enabled.

Implantable medical device and method for physiological event monitoring

A system and method are provided for the detection of acute myocardial infarction (AMI) using a staged approach for accurate and rapid detection. Physiological signals in a patient's body are sensed and corresponding physiological parameters are derived in a staged approach in order to determine the probability that AMI is occurring in a patient in a first detection stage. If the computed probability from physiological signals indicates the possibility of AMI, then the patient is prompted, such as through a patient-wearable device, to answer specific AMI-related questions to assist in diagnosis of AMI in a second stage. AMI is detected when the computed probability in the second stage exceeds a predefined detection threshold. A patient or physician alert may then be generated, which may further include the transfer of data via a communication link or network, in response to an AMI detection signal.

System and method for the detection of acute myocardial infarction

A medical device system and method for monitoring a patient include a monitoring device for storing data relating to the patient and a digital pen for digitizing and storing data handwritten by the patient. A control module is configured to aggregate data stored by the monitoring device and handwritten data stored by the digital pen.

Digital pen to capture data in ambulatory monitored patients

An implantable medical device identifies onset and/or progression of left ventricular dysfunction (LVD). The implantable medical device receives a signal that represents electrical activity within a heart, e.g., an electrogram signal, and digitally processes the signal to assess left ventricular function. In particular, the implantable medical device measures at least one characteristic of QRS complexes within the signal, and assesses left ventricular function based on measurements. The implantable medical device may, for example, measure the width of the QRS complexes and/or the amplitude of the R-waves within the QRS complexes. The implantable medical device may alert a patient or clinician of the onset or progression of LVD, and may control delivery of therapies, such as rate-responsive pacing and cardiac resynchronization pacing, based on the measurements. The implantable medical device may also control delivery of a drug by an implanted drug delivery device, e.g., drug pump, based on the measurements.

Monitoring QRS complex to identify left ventricular dysfunction

An implantable medical device operates to promote intrinsic ventricular depolarization according to a pacing protocol. The medical device operates to promote intrinsic conduction by providing elongated AV intervals or operating in an atrial based pacing mode. Conduction checks to determine if AV conduction is present are performed on a graduated or progressive scale to facilitate intrinsic emergence.

Implantable medical device with ventricular pacing protocol including progressive conduction search

An implantable medical device operates to promote intrinsic ventricular depolarization according to a pacing protocol. The medical device determines a course of action based upon the presence or absence of sensed ventricular activity. The device further determines whether that activity is properly conducted or the result of a PVC or nodal rhythm.

Implantable medical device with ventricular pacing protocol

An implantable medical device operates to promote intrinsic ventricular depolarization according to a pacing protocol. The medical device monitors the number of attempts made to promote intrinsic conduction in comparison with the number of successful cardiac cycles to determine an efficiency value.

System and method for determining an effectiveness of a ventricular pacing protocol for an implantable medical device

An implantable medical device operates to promote intrinsic ventricular depolarization according to a pacing protocol. The medical device monitors the AV interval and adjusts the Ventricular Pacing Protocol if the AV interval exceeds a threshold when the cardiac rate is elevated.

Techniques for stabilizing the rate of a ventricle, during conducted atrial fibrillation for example, adjust the escape interval of an implantable medical device to increase or decrease the pacing rate. In some embodiments, the escape interval is adjusted to achieve and maintain a percentage of pacing. In other embodiments, the stability of the ventricular rate is quantified as a function of measured R-R intervals, and the escape interval is adjusted to achieve and maintain a level of stability. In still other embodiments, a mean compensatory pause length is determined, and the escape interval is adjusted as a function of the mean compensatory pause length, to maintain the escape interval at or near the mean compensatory pause length.

Ventricular rate stabilization

A method of pacing cardiac tissue using an implantable medical device is provided. A first fibrillation-indicative interval is determined based on a first fibrillation-indicative event. A first adjusted pacing interval, wherein the first adjusted pacing interval is shorter than the first fibrillation-indicative interval, is determined and the cardiac tissue is paced based on the first adjusted pacing interval. If the cardiac tissue is not captured by pacing at the first adjusted pacing interval, an additional fibrillation-indicative interval is determined based on an additional earlier fibrillation-indicative event. An additional adjusted pacing interval, wherein the additional adjusted pacing interval is shorter than the additional fibrillation-indicative interval is determined and the cardiac tissue is paced based on the additional adjusted pacing interval.

Method and system for preventing atrial fibrillation by rapid pacing intervention

A method of measuring a source impedance of at least one cardiac electrical signal in a mammalian heart is provided. A first amplifier system is operated. A first signal from a chamber of the heart is received. The first signal is passed through a first amplifier. A second amplifier system is then operated. A second signal from the chamber of the heart is received. The second signal is passed through a second amplifier. Finally, the source impedance of at least one cardiac electrical signal is calculated. The source impedance is based on the amplified first signal and the amplified second signal.

Growing community of inventors

Brummen, Netherlands

Willem Boute